Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study.
Pommier R, Fisher G, Wolin E, Kunz P, Liyanage N, Pitman Lowenthal S, Mirakhur B, Shaheen M, Vinik A. Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study. Journal Of Clinical Oncology 2017, 35: 378-378. DOI: 10.1200/jco.2017.35.4_suppl.378.Peer-Reviewed Original ResearchLanreotide depotCarcinoid syndromeNeuroendocrine tumorsSymptomatic controlSevere diarrheaOCT useInteractive voice/web response systemPatient-reported symptomsWeb response systemSeverity of symptomsOCT-LARRescue medicationNET patientsWeek 12LAN treatmentPlaceboCS symptomsWk 12Symptom dataDiarrheaMean percentageSymptomsPatientsEfficacyBiochemical responses